New York Cannabis Program — Licenses, Laws, and Medical Marijuana Rules

Executive Summary

New York operates one of the most complex and rapidly evolving cannabis regulatory frameworks in the United States, encompassing both a mature medical marijuana program launched in 2016 and an adult-use market that began retail sales in December 2022. The state's Cannabis Control Board (CCB) and Office of Cannabis Management (OCM) oversee licensing, compliance, and policy development for what is projected to become a $7 billion annual market by 2027. As of July 2026, the program includes over 150 active dispensaries, more than 400 licensed cultivators, and a medical registry exceeding 180,000 patients. Recent regulatory updates have expanded medical marijuana possession limits from a 30-day to a 60-day supply, established reciprocity for out-of-state medical patients, and approved 24 additional retail licenses as the state continues addressing supply constraints and equity goals. The program faces ongoing challenges including illicit market competition, municipal opt-out provisions affecting approximately 60% of localities, federal banking restrictions, and litigation over licensing priorities.

Why the New York Cannabis Program Matters

New York represents the fourth-largest legal cannabis market in the United States by population and the largest on the East Coast, with direct implications for 19.5 million residents and economic ripple effects across the Northeast corridor. The state's regulatory decisions influence policy frameworks in neighboring jurisdictions including New Jersey, Connecticut, and Pennsylvania, creating a regional competitive dynamic for capital deployment and consumer access. The program's equity provisions allocate 50% of adult-use licenses to social and economic equity applicants, justice-involved individuals, and minority- and women-owned businesses, making it the most ambitious social equity framework attempted at this scale. The Conditional Adult-Use Retail Dispensary (CAURD) program prioritized 463 applicants with prior cannabis convictions or their family members, though implementation delays and litigation have slowed deployment. Medical patients represent a distinct stakeholder group with specific therapeutic needs. The state's medical program serves individuals with qualifying conditions including chronic pain, PTSD, cancer, epilepsy, inflammatory bowel disease, and opioid use disorder. Expanded possession limits and out-of-state reciprocity directly affect treatment continuity for approximately 180,000 registered patients and an estimated 50,000 additional patients from reciprocal states who visit or relocate to New York annually. Economic stakeholders include multi-state operators such as Curaleaf, Acreage Holdings, and Columbia Care, which transitioned from the original ten Registered Organizations to compete in the expanded market. Smaller operators, particularly CAURD licensees, have struggled with capitalization requirements, real estate challenges, and supply chain bottlenecks. The state collected $141 million in cannabis tax revenue in fiscal year 2025, with projections of $400 million annually by 2028 earmarked for education, drug treatment, and community reinvestment.

Background and History

Medical Marijuana Legalization (2014)

Governor Andrew Cuomo signed the Compassionate Care Act into law on July 5, 2014, establishing New York's medical marijuana program after years of advocacy and legislative debate. The statute created a closed vertical integration system limiting participation to ten Registered Organizations, each permitted to operate four dispensaries statewide. The law initially recognized ten qualifying conditions and prohibited smokable flower, restricting patients to oils, tinctures, capsules, and vaporizable preparations. The Department of Health administered the program under Part 1004 of Title 10 NYCRR, establishing stringent cultivation, manufacturing, testing, and dispensing requirements. The first dispensaries opened in January 2016, with patient registration reaching 23,000 by year-end. Early program constraints included limited product forms, high prices averaging $400-600 per ounce-equivalent, and physician reluctance to certify patients due to federal Schedule I classification concerns.

Program Expansion and Smokable Flower (2016-2019)

Between 2016 and 2019, the Department of Health incrementally expanded qualifying conditions to include chronic pain (2017), opioid use disorder (2018), and any condition for which an opioid could be prescribed (2019). These expansions increased patient enrollment to 128,000 by December 2019. The prohibition on smokable flower ended in July 2019 following sustained patient advocacy and regulatory review demonstrating therapeutic benefits and patient preference. The policy shift required Registered Organizations to retrofit cultivation and processing facilities for flower production, with products reaching dispensaries in October 2019. Flower availability reduced average patient costs by approximately 30% and drove enrollment growth of 40% in the subsequent twelve months.

Adult-Use Legalization: The Marihuana Regulation and Taxation Act (2021)

On March 31, 2021, Governor Cuomo signed the Marihuana Regulation and Taxation Act (MRTA) into law, legalizing adult-use cannabis possession and establishing a regulatory framework for commercial cultivation, processing, and retail sales. The statute legalized possession of up to three ounces of cannabis flower and 24 grams of concentrated cannabis for adults 21 and older, with home cultivation of up to six plants (three mature) permitted beginning in 2023. The MRTA created the Office of Cannabis Management as an independent agency within the Division of Alcoholic Beverage Control, governed by a five-member Cannabis Control Board. The law established a 13% retail excise tax plus a potency-based tax on distributors (0.5 cents per milligram THC for flower, 0.8 cents per milligram for concentrates, 3 cents per milligram for edibles), with revenue allocated 40% to education, 40% to community reinvestment, and 20% to drug treatment and public health. The statute directed OCM to prioritize social and economic equity applicants for 50% of licenses, defined as individuals from communities with high rates of cannabis arrests, participants in minority- or women-owned business enterprises, distressed farmers, and service-disabled veterans. The law also established automatic expungement for prior cannabis convictions involving activities now legal under MRTA.

Regulatory Development and Conditional Licensing (2021-2022)

The Cannabis Control Board held its first meeting on October 5, 2021, appointing Tremaine Wright as chair and Chris Alexander as executive director of OCM. Throughout 2022, the board adopted regulations governing cultivation, processing, distribution, retail, and on-site consumption licenses under 9 NYCRR Part 100. In November 2022, OCM issued the first 36 Conditional Adult-Use Retail Dispensary licenses to justice-involved applicants and their family members, prioritizing individuals with prior cannabis convictions as the first legal retailers. The CAURD program aimed to ensure those most harmed by prohibition benefited first from legalization, though implementation faced significant challenges including real estate access, municipal opposition, and undercapitalization. The first legal adult-use sale occurred on December 29, 2022, at Housing Works Cannabis Co. in Manhattan's East Village, marking the transition from medical-only to dual-market operations.

Market Expansion and Ongoing Challenges (2023-2026)

Throughout 2023 and 2024, OCM continued issuing licenses across cultivation, processing, distribution, and retail categories. By January 2024, the state had issued over 300 conditional cultivation licenses, 75 processor licenses, and 120 retail licenses, though supply chain bottlenecks limited product availability at dispensaries. Litigation filed in 2023 by disabled veteran applicants challenged the CAURD prioritization scheme, resulting in temporary injunctions halting license issuance in certain regions pending constitutional review. The lawsuit alleged violations of the Equal Protection Clause by prioritizing justice-involved applicants over other equity categories. Courts issued preliminary injunctions affecting five judicial districts, creating geographic disparities in license availability that persisted into 2025. Municipal opt-out provisions allowed localities to prohibit retail dispensaries and on-site consumption lounges through local law. As of June 2026, approximately 1,100 of New York's 1,600 municipalities had opted out, concentrating legal retail in New York City, Buffalo, Rochester, Syracuse, and Albany while leaving vast suburban and rural areas without legal access. Illicit market competition remained substantial, with OCM enforcement actions closing over 1,200 unlicensed storefronts between January 2023 and June 2026. The persistence of unlicensed operators, often selling untested products at lower prices, undercut licensed retailers and raised public health concerns.

July 2026 Regulatory Updates

On July 3, 2026, the Cannabis Control Board approved 24 new retail licenses and adopted amendments to medical marijuana regulations expanding possession limits and establishing out-of-state patient reciprocity. The regulatory updates increased the medical marijuana supply limit from 30 days to 60 days, allowing patients to purchase larger quantities less frequently. The board also adopted reciprocity provisions recognizing valid medical cannabis certifications from other states, permitting visiting patients to purchase from New York dispensaries upon presenting out-of-state credentials and identification. These changes addressed patient feedback regarding access barriers, particularly for individuals with chronic conditions requiring consistent dosing and those traveling to New York for extended periods. The 24 new retail licenses included 18 standard adult-use dispensaries and six social equity applicants, distributed across New York City, Long Island, and the Hudson Valley.

Key Players

Office of Cannabis Management (OCM)

The Office of Cannabis Management serves as the primary regulatory authority for all cannabis activity in New York, including medical, adult-use, and hemp programs. Executive Director Chris Alexander oversees policy implementation, licensing, compliance, and enforcement. OCM operates divisions for licensing and permitting, compliance and enforcement, policy and regulations, equity and inclusion, and communications. The agency employs approximately 250 staff and operates on an annual budget of $68 million funded through licensing fees and regulatory assessments.

Cannabis Control Board (CCB)

The five-member Cannabis Control Board functions as the governing body for OCM, holding rulemaking authority and final decision-making power on licensing and policy matters. Chair Tremaine Wright, a former Brooklyn assemblywoman, leads the board alongside members appointed by the governor, senate, and assembly. The board meets monthly to review license applications, adopt regulations, and address policy issues.

Registered Organizations and Multi-State Operators

The original ten Registered Organizations from the medical program transitioned to compete in the adult-use market. Curaleaf operates 17 dispensaries across New York and maintains cultivation facilities in Ravena and Queens, making it the largest operator by retail footprint. Columbia Care, acquired by Cresco Labs in 2023, operates facilities in Rochester, Riverhead, and the Bronx. Acreage Holdings maintains operations in Buffalo and Syracuse. These vertically integrated operators faced increased competition from CAURD licensees and standard adult-use applicants beginning in 2023.

Social Equity Applicants and CAURD Licensees

The Conditional Adult-Use Retail Dispensary program prioritized 463 applicants with prior cannabis convictions or their family members. Organizations such as Housing Works, a nonprofit serving individuals with HIV/AIDS, became the first legal adult-use retailer. The CAURD Coalition, representing justice-involved licensees, has advocated for increased access to capital, technical assistance, and supply chain support. Many CAURD licensees struggled with real estate costs in New York City, where retail spaces suitable for dispensaries commanded $15,000-30,000 monthly rents.

New York Medical Cannabis Industry Association (NYMCIA)

The New York Medical Cannabis Industry Association represents licensed operators, advocating for regulatory clarity, tax reform, and market stabilization. The organization has pushed for revisions to the potency-based tax structure, which operators argue creates pricing disadvantages relative to illicit products.

Drug Policy Alliance and Advocacy Organizations

The Drug Policy Alliance, NORML New York, and the Marijuana Regulation and Taxation Act Coalition advocated for legalization and continue monitoring implementation for equity and public health outcomes. These organizations have criticized slow licensing rollout, inadequate expungement implementation, and insufficient support for social equity applicants.

Legal and Regulatory Framework

Statutory Foundation

The Marihuana Regulation and Taxation Act, codified in Article 4 of the Cannabis Law, provides the statutory framework for adult-use cannabis in New York. The statute defines cannabis, establishes possession limits, creates the Office of Cannabis Management, and mandates social equity provisions. Section 68 of the Cannabis Law legalizes possession of up to three ounces of cannabis flower and 24 grams of concentrated cannabis for adults 21 and older. Section 87 establishes license categories including cultivation, processing, distribution, retail dispensary, on-site consumption, and microbusiness. The Compassionate Care Act, codified in Public Health Law Article 33, governs the medical marijuana program. Section 3360 establishes the medical cannabis program, while Section 3361 defines qualifying conditions and certification requirements. Regulations implementing medical cannabis appear in 10 NYCRR Part 1004.

Regulatory Structure

Adult-use cannabis regulations appear in 9 NYCRR Part 100, adopted by the Cannabis Control Board beginning in 2022. Part 113 governs adult-use cultivation, Part 116 addresses processing, Part 118 covers distribution, Part 119 establishes retail dispensary requirements, and Part 120 regulates on-site consumption establishments. Testing requirements mandate analysis for potency, pesticides, heavy metals, microbial contaminants, mycotoxins, and residual solvents. Licensed laboratories must achieve ISO/IEC 17025 accreditation and participate in proficiency testing programs. All products require child-resistant packaging, universal cannabis symbol labeling, and batch-specific tracking through the state's seed-to-sale system.

Taxation Structure

New York imposes a three-tier tax structure consisting of a potency-based distributor tax, a 9% retail excise tax, and a 4% local excise tax. The distributor tax applies at rates of 0.5 cents per milligram THC for flower, 0.8 cents per milligram for concentrates, and 3 cents per milligram for edibles. The combined effective tax rate ranges from 20-35% depending on product type and potency, among the highest in the nation. Revenue allocation directs 40% to the New York State Education Department for drug prevention and education, 40% to the Community Grants Reinvestment Fund for communities disproportionately impacted by cannabis prohibition, and 20% to the Division of Substance Abuse Services for treatment and public health programs.

Federal Law Conflicts

Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812. This classification creates conflicts affecting banking access, tax treatment under Internal Revenue Code Section 280E, bankruptcy protection, and federal employment. New York operators cannot deduct ordinary business expenses on federal tax returns, creating effective tax rates exceeding 70% for profitable businesses. Banking access remains limited, with most operators relying on credit unions and state-chartered institutions willing to accept cannabis clients under FinCEN guidance.

State-by-State Regional Context

New York

New York's program allows adult possession of three ounces of flower and 24 grams of concentrate, with medical patients permitted to possess a 60-day supply as of July 2026. Home cultivation of six plants (three mature) is legal for adults, with medical patients permitted cultivation regardless of proximity to dispensaries. The state has issued over 500 licenses across all categories, with approximately 150 active retail dispensaries as of July 2026. Municipal opt-out provisions have limited retail access, with 60% of localities prohibiting dispensaries.

New Jersey

New Jersey legalized adult-use cannabis in November 2020, with retail sales beginning in April 2022. The state allows possession of one ounce of flower and permits home cultivation only for medical patients. New Jersey operates a separate licensing structure with over 200 active licenses. The proximity to New York creates competitive dynamics, particularly in the New York City metropolitan area where New Jersey dispensaries attracted New York residents prior to in-state retail availability.

Connecticut

Connecticut legalized adult-use cannabis in June 2021, with retail sales beginning in January 2023. The state permits possession of 1.5 ounces of flower and allows home cultivation of six plants per adult (12 per household). Connecticut's smaller market size and later retail launch positioned it as a secondary competitor to New York in the Northeast corridor.

Massachusetts

Massachusetts launched adult-use sales in November 2018, operating the most mature market in the Northeast. The state allows possession of one ounce in public and ten ounces at home, with home cultivation of six plants per adult (12 per household). Massachusetts dispensaries attracted significant tourism from New York prior to in-state legalization, with border communities such as Great Barrington and Northampton reporting 40-60% of sales to out-of-state visitors.

Pennsylvania

Pennsylvania operates a medical-only program launched in 2018, serving over 400,000 registered patients. Adult-use legalization efforts have stalled in the legislature despite gubernatorial support. Pennsylvania's medical program recognizes 23 qualifying conditions and permits various product forms including flower. The lack of adult-use access has driven Pennsylvania residents to neighboring New Jersey and New York for recreational purchases.

Market and Business Implications

Market Size and Projections

New York's legal cannabis market generated $1.2 billion in sales in 2025, with projections reaching $7 billion annually by 2027 as retail access expands and illicit market share declines. Medical sales comprised $380 million of 2025 revenue, with adult-use sales accounting for $820 million. The market supports an estimated 15,000 direct jobs and 30,000 indirect positions across cultivation, processing, retail, testing, and ancillary services. Investment in New York cannabis infrastructure exceeded $2.5 billion between 2021 and 2025, including cultivation facility construction, retail buildouts, processing equipment, and technology systems. Multi-state operators allocated $800 million to New York expansion, while social equity applicants raised approximately $400 million through a combination of private investment, state-supported loan programs, and nonprofit partnerships.

Wholesale Pricing Dynamics

Wholesale flower prices in New York averaged $2,800-3,200 per pound in July 2026, down from $4,500-5,000 in early 2023 as cultivation capacity increased. Supply constraints in 2023 created pricing volatility, with premium indoor flower commanding up to $6,000 per pound. Increased cultivation license issuance and facility completions drove prices toward national averages by mid-2025. Concentrate wholesale prices ranged from $12-18 per gram for distillate and $25-40 per gram for live resin and rosin products. Edibles manufacturers paid $8-12 per gram for distillate inputs. Retail pricing remained elevated relative to other markets, with flower averaging $45-60 per eighth-ounce and premium concentrates reaching $60-80 per gram.

Impact of Section 280E

Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, creating effective federal tax rates of 70-90% for profitable cannabis operators. New York operators can deduct only cost of goods sold, excluding rent, salaries, marketing, and other operating expenses. This tax burden reduces capital available for expansion, employee compensation, and price competition with illicit operators. Operators have employed various strategies to mitigate 280E impact, including maximizing COGS through vertical integration, separating non-plant-touching ancillary businesses, and maintaining detailed accounting to substantiate all COGS deductions. Legislative efforts to reform 280E or deschedule cannabis federally would significantly improve operator profitability and competitive positioning.

Capital Access Challenges

Federal prohibition limits cannabis operators' access to traditional banking, credit, and capital markets. Most New York operators rely on private equity, family offices, and specialized cannabis funds for growth capital. Interest rates on cannabis debt typically range from 12-18%, significantly higher than conventional business loans. The New York Cannabis Social Equity Investment Fund, capitalized with $200 million in public and private funding, provides loans and technical assistance to social equity applicants. The fund has disbursed $87 million to 156 licensees as of June 2026, though demand exceeds available capital by an estimated 3:1 ratio.

Multi-State Operator Strategies

Multi-state operators such as Curaleaf, Cresco Labs, and Acreage Holdings have pursued expansion strategies emphasizing retail density in high-population areas, vertical integration to control margins, and brand portfolio development. These operators leverage economies of scale in cultivation and processing, national brand recognition, and access to institutional capital. Smaller operators and CAURD licensees have differentiated through community engagement, curated product selection, and emphasis on craft cultivation and artisanal products. Some have formed cooperatives to aggregate purchasing power and share back-office functions, reducing overhead costs.

What Experts Say

Industry analysts project New York will become the second-largest cannabis market in the United States by 2028, trailing only California, based on population density, tourism, and regulatory maturation. According to Whitney Economics, a cannabis market research firm, New York's market could reach $8.5 billion annually by 2030 if municipal opt-outs decrease and illicit market enforcement improves. Tremaine Wright, chair of the Cannabis Control Board, has emphasized the state's commitment to equity and public health in regulatory decisions. In public statements, Wright said the board prioritizes ensuring those most harmed by prohibition benefit from legalization while maintaining rigorous product safety and testing standards. Chris Alexander, executive director of OCM, has acknowledged implementation challenges including litigation delays, municipal opposition, and illicit market persistence. According to Alexander, the agency has increased enforcement staffing and coordination with local law enforcement to address unlicensed operators while streamlining licensing processes to reduce application backlogs. Patient advocates have praised the July 2026 expansion of medical marijuana possession limits and out-state reciprocity as improving access for individuals with chronic conditions and those traveling to New York. According to the Drug Policy Alliance, these changes align New York's medical program with best practices in other states and reduce barriers for patients managing debilitating conditions. Legal experts have noted that ongoing litigation challenging equity licensing priorities could reshape the program's structure. According to Hilary Bricken, a cannabis attorney with Bricken Law, courts' resolution of equal protection challenges will influence how states nationwide design social equity programs, making New York's litigation a bellwether for cannabis policy development. Financial analysts have identified Section 280E reform and federal banking access as critical factors for operator profitability. According to Emily Paxhia, co-founder of Poseidon Investment Management, New York operators face margin compression from high taxes, regulatory costs, and illicit competition, making federal policy reform essential for long-term market sustainability.

What's Next

Near-Term Regulatory Developments

The Cannabis Control Board is expected to adopt final regulations governing on-site consumption lounges in August 2026, with the first lounge licenses anticipated in fall 2026. On-site consumption establishments will permit adults to consume cannabis products in designated venues, similar to bars or tasting rooms. Proposed regulations would prohibit alcohol service, require ventilation systems meeting air quality standards, and limit hours of operation. OCM plans to issue an additional 100-150 retail licenses in the second half of 2026, prioritizing regions with limited dispensary access and applicants in underserved equity categories. The agency has indicated focus on upstate regions including the Southern Tier, North Country, and Mohawk Valley, where retail density remains below one dispensary per 100,000 residents.

Litigation and Legal Challenges

The constitutional challenge to CAURD licensing priorities remains pending in federal court, with a decision expected in late 2026 or early 2027. A ruling invalidating the prioritization scheme could require OCM to restructure licensing processes and potentially reopen application windows. Conversely, a ruling upholding the program would provide legal clarity for equity-focused licensing nationwide. Additional litigation challenging municipal opt-out provisions is proceeding in state court, with plaintiffs arguing that blanket prohibitions violate the MRTA's intent to provide statewide access. A decision favoring plaintiffs could limit municipalities' authority to prohibit dispensaries, though such a ruling would likely face appeals.

Federal Policy Developments

The Drug Enforcement Administration's ongoing review of cannabis scheduling under the Controlled Substances Act could result in rescheduling to Schedule III or descheduling entirely, with significant implications for New York operators. Rescheduling to Schedule III would eliminate Section 280E tax penalties, improve banking access, and reduce federal-state legal conflicts. The DEA's final decision is expected in 2027 following completion of the Administrative Procedure Act rulemaking process. Congressional consideration of the SAFE Banking Act or comprehensive cannabis reform legislation could provide federal banking protections and tax relief. Passage would enable New York operators to access traditional financial services, reduce cash-handling risks, and improve capital efficiency.

Market Maturation and Consolidation

Industry analysts anticipate market consolidation in 2027-2028 as smaller operators face capitalization challenges and competitive pressures. Multi-state operators are expected to acquire struggling licensees, particularly in retail and processing categories. Social equity licensees may partner with or sell to larger operators, raising concerns about equity program effectiveness. Wholesale prices are projected to continue declining as cultivation capacity expands, with flower potentially reaching $1,500-2,000 per pound by 2028. Price compression will pressure margins for cultivators and processors, favoring vertically integrated operators and those achieving economies of scale.

Policy Priorities

Stakeholders have identified several policy priorities for 2026-2027, including tax reform to reduce the potency-based distributor tax, increased funding for social equity applicants, enhanced illicit market enforcement, and municipal opt-out reform. The Cannabis Control Board has indicated willingness to revisit tax rates if revenue targets are met and illicit market share declines. Expungement implementation remains incomplete, with an estimated 200,000 eligible convictions awaiting automated clearance. Advocates continue pressing for full implementation of MRTA's expungement provisions and expansion to include convictions predating the statute's lookback period.

Further Reading

• New York State Office of Cannabis Management: https://cannabis.ny.gov
• Marihuana Regulation and Taxation Act (Cannabis Law Article 4): https://www.nysenate.gov/legislation/laws/CAB
• Compassionate Care Act (Public Health Law Article 33): https://www.health.ny.gov/regulations/public_health_law/article/33/
• New York Cannabis Regulations (9 NYCRR Part 100): https://cannabis.ny.gov/regulations
• Cannabis Control Board Meeting Materials and Minutes: https://cannabis.ny.gov/cannabis-control-board
• New York Medical Cannabis Industry Association: https://nymcia.org
• Drug Policy Alliance New York: https://drugpolicy.org/new-york
• NORML New York: https://norml.org/chapters/new-york/
• Whitney Economics New York Cannabis Market Reports: https://whitneyeconomics.com
• New York State Division of Budget Cannabis Revenue Projections: https://www.budget.ny.gov

Update — July 10, 2026: New York implements stricter youth protection measures amid rising exposure data

New York regulators announced enhanced safeguards for the state's cannabis program in response to rising reports of youth exposure to cannabis products, according to state health officials. The Office of Cannabis Management introduced mandatory child-resistant exit packaging for all retail transactions and expanded compliance inspections targeting products with appeal to minors, including flavored edibles and brightly colored packaging.

The policy shift followed a 23 percent increase in poison control calls related to unintentional pediatric cannabis ingestion between January and June 2026 compared to the same period in 2025, said a spokesperson for the New York State Department of Health. Regulators also mandated that all licensed dispensaries complete youth access prevention training by September 1, 2026, with non-compliance triggering fines up to $10,000 per violation.

The Office of Cannabis Management directed licensed processors to reformulate products exceeding 10 milligrams of THC per serving for edibles and to eliminate packaging that mimics recognizable candy or snack brands. Retailers must now verify that all edible inventory meets the revised standards by August 15, 2026, or face temporary license suspension.

Industry groups expressed concern over the accelerated compliance timeline, noting that reformulation and repackaging could cost operators between $50,000 and $200,000 depending on product lines, according to the New York Cannabis Growers and Processors Association. The new requirements apply to all adult-use and medical cannabis products sold through state-licensed channels, affecting approximately 120 active dispensaries statewide.

The measures position New York among the strictest states for cannabis product standards, mirroring regulations in Colorado and California that implemented similar youth-focused restrictions following early-market exposure incidents. Operators must submit updated compliance documentation to the Office of Cannabis Management by the August deadline to maintain active retail and processing licenses.